C3 looks to Chinese market with Helicon
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Wednesday, 23 November, 2005 - 12:08
Clinical Cell Culture Ltd has announced the appointment of Perth-based North Asia-specialist Helicon Group Ltd as its distributor of its ReCell skin regeneration product in China.
C3 said Helicon will act through its Chinese partner Cobra Bio Health Services International.
The arrangement follows C3's recent announcement that it had secured a Korean manufacturer for another of its skin products.
Helicon is an Australian registered and headquartered company established specifically to identify and exploit
niche market opportunities in the biomedical markets of North Asia, particularly China and to participate in the
significant growth that has been projected for these markets over the next 25 years
Companies: